Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.30 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.30 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.30 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL497349 | 0.82 | P2RY14 (0.34) | P2RY14P2RY2P2RY4BTN3A1 | |
| SCHEMBL25370472 | 0.81 | CTSA (0.38) | CTSAACHE | |
| SCHEMBL14189792 | 0.81 | CTSA (0.33) | CTSAACHE | |
| SCHEMBL18291794 | 0.79 | BTN3A1 (0.32) | P2RY14P2RY2P2RY4BTN3A1 | |
| SCHEMBL26316292 | 0.78 | HMGCR (0.36) | CTSAACHE | |
| SCHEMBL2032723 | 0.77 | LPAR3 (0.35) | ACHEP2RY14P2RY2P2RY4BTN3A1 | |
| SCHEMBL2030636 | 0.77 | ACHE (0.38) | ACHEBTN3A1 | |
| SCHEMBL12563529 | 0.76 | LPAR3 (0.38) | CTSAACHEBTN3A1 | |
| SCHEMBL27457178 | 0.76 | MVD (0.33) | — | |
| SCHEMBL11952574 | 0.76 | BTN3A1 (0.38) | P2RY14P2RY2P2RY4BTN3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230057718-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| US-20210401994-A1 | SIRNA CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2021-12-30 | — | — | US | disclosed |
| US-20210275564-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2021-09-09 | — | — | US | disclosed |
| US-20200048638-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401994-A1 | SIRNA CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | VARS1, IGSF11, MCTS1 | CTSA 3919/4885ACHE 4759/4885P2RY14 4866/4885 |
| US-20210275564-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, AND USE THEREOF | NSUN2, SLC10A1, BCDIN3D | CTSA 3795/4885ACHE 4704/4885P2RY14 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.